Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: StocksDATsoar who wrote (76189)	2/16/2000 7:19:00 PM
From: dk10438	Read Replies (1) \| Respond to of 108040

didnt mean to be inflammatory, but just giving you my opinion, there are lots of new advances in the field of radiation oncology, hyperthermia however is not new to this field. perhaps you have a good understanding of cancer, how it spreads, and how we treat it. i know i do. although there are many aspects which make hyperthermia appealing, it has not really impacted clinical practice. furthermore, retrospective single institutional data, whether it be from duke, harvard, stanford, etc is generally not viewed as favorably as multi-institutional prospectively randomized data. at the very least, the data needs to be confirmed by other institutions. i can tell you for sure, hyperthermia is not in common usage in general practice, that is a fact, if you want to believe that it will become popularized by duke data, go ahead and load the boat.... again, i dont be mean to be rude or inflammatory, good luck